Product information and disease description Place of product in therapy Approaches to treatment

Place in treatment, anticipated use, and care setting

4 evidence topics · 8 sources

Summary

Tiratricol is approved in the United States (September 2026) for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency and in the EU (February 2025) for peripheral thyrotoxicosis in MCT8 deficiency from birth; it is the first FDA-approved treatment for the disease. The 2024 European Thyroid Association guideline recommends TRIAC (strong recommendation) or DITPA (weak recommendation) with long-term therapy, and suggests combined levothyroxine and propylthiouracil only when thyroid hormone analogues are unavailable. The label advises against combining tiratricol with other thyroid medications such as levothyroxine and propylthiouracil. Dosing is individualized by body weight, total T3 measured by LC-MS/MS, and signs and symptoms of thyrotoxicosis, and the suspension can be given by mouth or through a feeding tube. A 2026 monitoring guideline notes that TRIAC costs substantially more than conventional thyroid hormone preparations and that treatment may be deferred in individual cases, such as patients without biochemical or cardiovascular evidence of thyrotoxicosis. Tiratricol does not replace supportive management of feeding difficulties, developmental disability, spasticity, or movement disorders. In the United States it is dispensed through PANTHERx Rare with the Egetis RareLink support program; before approval, the U.S. Expanded Access Program included 17 hospitals and approximately 60 treated individuals.

Use with other thyroid medications

“Taking EMCITATE in combination with thyromimetic products or products used to treat thyroid conditions (e.g., levothyroxine, propylthiouracil, and carbimazole) may increase the risk of thyrotoxicosis or hypothyroidism and should be avoided.” (opens the prescribing information at this quote)

Cost relative to conventional thyroid hormone preparations

“TRIAC is associated with substantially higher costs than conventional TH preparations, requiring individualized cost-benefit evaluation within different healthcare systems.” (opens the source at this quote in a new tab)

Circumstances in which treatment may be deferred

“Although treatment to reduce peripheral thyrotoxicosis is generally recommended in MCT8 deficiency, therapy may occasionally be deferred in individual cases, for example, in the absence of biochemical or cardiovascular evidence of thyrotoxicosis (which may occur in patients with milder phenotypes), intolerance to treatment, limited access to therapy, or following individualized clinical assessment.” (opens the source at this quote in a new tab)